Genocea Biosciences and the Naval Medical Research Center have entered into a cooperative research and development agreement for the identification of antigens to be used in the development of vaccines against malaria.

Under the CRADA, Genocea will apply its proprietary technology to identify novel T-cell antigens from a proteomic screen of Plasmodium falciparum, the parasite that causes malaria in humans. Based on that information, NMRC will develop a candidate vaccine.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.